Do you want to read an article? Please log in or register.
Efficacy and Safety of Anthocyanin-Rich Extract in Patients with Ulcerative Colitis: A Randomized Controlled Trial
Inflammatory Bowel Disease
COMMENTED
Related content
Inflammatory Bowel Disease
Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis
J Crohns Colitis
D'Haens G, Danese S, Panaccione R, Rubin DT, Peyrin-Biroulet L, Matsuoka K, Loftus EV Jr, Kobayashi T, Elsharkawi W, Miceli R, Ahmed S, Luo Y, Napoli A, Vaile J, Dornic Q, Patel A, Schreiber S
doi: 10.1093/ecco-jcc/jjaf080
Further Publications
Generalizability of Randomized Controlled Trials to Routine Clinical Care in Ulcerative Colitis
Inflamm Bowel Dis
Chhibba T, Frolkis A, Stein LR, Lee S, Schill K, Mitevska E, Judge AK, Martin ML, Martin M, Novak KL, Lu C, Ingram RJM, Chan MM, Shukla T, Seow CH, Kaplan GG, Ananthakrishnan AN, Panaccione R, Ma C
doi: 10.1093/ibd/izaf012
Inflammatory Bowel Disease
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Crohn's Disease and Ulcerative Colitis: 2-Year Results from Open-Label Extensions of Two Randomized Controlled Trials (LIBERTY)
J Crohns Colitis
Colombel JF, Sandborn WJ, Schreiber S, Danese S, Kłopocka M, Kierkuś J, Kulynych R, Gonciarz M, Sołtysiak A, Smoliński P, Srećković S, Valuyskikh E, Lahat A, Horyński M, Gasbarrini A, Osipenko M, Borzan V, Kowalski M, Saenko D, Sardinov R, Lee SJ, Kim S, Bae Y, Lee S, Lee S, Lee JH, Kim JM, Park G, Lee J, Lee J, Ryu JY, Sands BE, Hanauer SB
doi: 10.1093/ecco-jcc/jjaf060
Inflammatory Bowel Disease
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study
Lancet Gastroenterol Hepatol
Panaccione R, Vermeire S, Danese S, Higgins PDR, Lichtenstein GR, Nakase H, Glover S, Colombel JF, Eccleston J, Kujawski M, Remple V, Yao X, Geng Z, Palac H, Sharma D, Suravaram S, Schreiber S
doi: 10.1016/S2468-1253(25)00017-2
Inflammatory Bowel Disease
Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program
Inflamm Bowel Dis
Sands BE, Dubinsky MC, Kotze PG, Vermeire S, Panaccione R, Long MD, Woolcott JC, Wu J, McDonnell A, Goetsch M, Bananis E, Yarur AJ
doi: 10.1093/ibd/izaf036
Hepatology
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial
J Hepatol
Levy C, Abouda GF, Bilir BM, Bonder A, Bowlus CL, Campos-Varela I, Cazzagon N, Chandok N, Cheent K, Cortez-Pinto H, Demir M, Dill MT, Eksteen B, Fenkel JM, Gilroy R, Ko HH, Jacobson IM, Kallis Y, Kugelmas M, Luketic V, Mangia A, Montano-Loza AJ, Mukhopadhya A, Olveira A, Patel BC, Pietrangelo A, Pradhan F, Salcedo M, Shiffman ML, Sprinzl K, Swann R, Thorburn D, Thuluvath PJ, Trivedi PJ, Turnes J, Zein CO, Gomes da Silva H, Jaitly S, Miller B, Milligan C, Tavenard A, Kowdley KV
doi: 10.1016/j.jhep.2025.04.025
Inflammatory Bowel Disease
No Impact of Concomitant Medications on Efficacy and Safety of Biologics and Small Molecules for Ulcerative Colitis
Clin Gastroenterol Hepatol
Ahuja D, Zou G, Solitano V, Syal G, Lee HH, Ma C, Jairath V, Singh S
doi: 10.1016/j.cgh.2024.08.040
RECOMMENDED
Inflammatory Bowel Disease
Effectiveness and safety of rectal tacrolimus in patients with ulcerative colitis. TACRO-TOPIC study of GETECCU
★ 1
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis
Fuentes-Valenzuela E, Bastón-Rey I, García-Alonso FJ, Elosua A, Zabalza San Martín L, Leo Carnerero E, Garcia de la Filia I, Pedraza Pérez A, Sáiz Chumillas RM, Pascual Oliver A, Muñoz Villafranca C, Moreno V, Suárez Ferrer C, Molina G, Ferreiro-Iglesias R, Vega Villaamil P, Gardeazábal Mateos D, Segarra-Ortega JX, Garrido Marín A, Doallo AI, Alonso-Galán H, Brunet-Mas E, Jimenez García N, López Romero-Salazar F, Velayos B, Carballo-Folgoso L, Pérez Santamaría C, Mata Román L, Núñez Ortiz A, Barrio J, Barreiro-de Acosta M, Gutiérrez-Casbas A, Young GETECCU group
doi: 10.1093/ecco-jcc/jjaf058
Inflammatory Bowel Disease
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Inflamm Bowel Dis
Sands BE, D'Haens G, Clemow DB, Irving PM, Johns JT, Gibble TH, Abreu MT, Lee SD, Hisamatsu T, Kobayashi T, Dubinsky MC, Vermeire S, Siegel CA, Peyrin-Biroulet L, Moses RE, Milata J, Panaccione R, Dignass A
doi: 10.1093/ibd/izae253